2.4. Intervention and Follow-up
The standard treatment for COVID-19 infection is sofosbuvir/daclatasvir + hydroxychloroquine, which both groups receive. Dosage and frequency of use of atazanavir + hydroxychloroquine are as follows: tab sofosbuvir/daclatasvir 400/60 mg oral daily for 7 to 10 days (produced by BakhtarBiochemistry pharmaceutical company, Iran) and oral hydroxychloroquine 400 mg stat then 200 twice daily for 7 to 14 days (produced by Macleod’spharmaceutical company, India). PTX 400 mg TDS was administered to the intervention group for 14 days (produced by Farabi Pharmaceutical company, Iran).